Robert Freedman

Dr. Robert Freedman

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Neuropharmacology
Verified
Journal Article
Closed access
MSMelissa L. Sinkus
Melissa L. Sinkus
SGSharon Graw
Sharon Graw
RFRobert Freedman
Robert Freedman
RRRandal G. Ross
Randal G. Ross
HLHenry Lester
Henry Lester
SLSherry Leonard
Sherry Leonard

14 January 2014 in Annual Review of Medicine
Verified
Journal Article
Closed access
RFRobert Freedman
Robert Freedman
α7-Nicotinic acetylcholine receptors have emerged as a potential therapeutic target for the treatment of neurocognitive dysfunctions in schizophrenia that are often resistant to existing antipsychotic drugs. Molecular evidence for involvement in schizophrenia of CHRNA7, the gene for the receptor subunit, in the neurobiology of deficits in attention is a critical rationale for the clinical study of α7-nicotinic receptor agonists to improve neurocognition. Initial clinical trials show enhancement of inhibitory neuron function related to sensory gating and increased attention and working memory, as well as improvement in negative symptoms such as anhedonia and alogia. Further development of this therapeutic strategy requires assessment of interactions with patients' heavy cigarette smoking and the relationship of this mechanism to the therapeutic effects of clozapine and olanzapine, both highly effective therapeutics with significant side effects.

13 March 1995 in Brain Research
Verified
Journal Article
Closed access
CBCharles R. Breese
Charles R. Breese
RFRobert Freedman
Robert Freedman
SLSherry S. Leonard
Sherry S. Leonard


2 December 2019 in Psychological Medicine
Verified
Journal Article
Closed access
PDF file
SHSharon K Hunter
Sharon K Hunter
MHM. Camille Hoffman
M. Camille Hoffman
ADAngelo D'Alessandro
Angelo D'Alessandro
KNKathleen Noonan
Kathleen Noonan
AWAnna Wyrwa
Anna Wyrwa
ALAmanda J. Law
Amanda J. Law
Background: Maternal inflammation in early pregnancy has been identified epidemiologically as a prenatal pathogenic factor for the offspring's later mental illness. Early newborn manifestations of the effects of maternal inflammation on human fetal brain development are largely unknown.Methods: Maternal infection, depression, obesity, and other factors associated with inflammation were assessed at 16 weeks gestation, along with maternal C-reactive protein (CRP), cytokines, and serum choline. Cerebral inhibition was assessed by inhibitory P50 sensory gating at 1 month of age, and infant behavior was assessed by maternal ratings at 3 months of age.Results: Maternal CRP diminished the development of cerebral inhibition in newborn males but paradoxically increased inhibition in females. Similar sex-dependent effects were seen in mothers' assessment of their infant's self-regulatory behaviors at 3 months of age. Higher maternal choline levels partly mitigated the effect of CRP in male offspring.Conclusions: The male fetal-placental unit appears to be more sensitive to maternal inflammation than females. Effects are particularly marked on cerebral inhibition. Deficits in cerebral inhibition 1 month after birth, similar to those observed in several mental illnesses, including schizophrenia, indicate fetal developmental pathways that may lead to later mental illness. Deficits in early infant behavior follow. Early intervention before birth, including prenatal vitamins, folate, and choline supplements, may help prevent fetal development of pathophysiological deficits that can have life-long consequences for mental health.

1 May 2019 in The Journal of Pediatrics
Verified
Journal Article
Closed access
RFRobert Freedman
Robert Freedman
SHSharon K. Hunter
Sharon K. Hunter
ALAmanda J. Law
Amanda J. Law
BWBrandie D. Wagner
Brandie D. Wagner
ADAngelo D'Alessandro
Angelo D'Alessandro
MHM. Camille Hoffman
M. Camille Hoffman